Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Olaparib for the treatment of BRCA-mutated advanced ovarian cancer.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists - 15 Jul 2016

Munroe Marklie, Kolesar Jill

Abstract excerpt

PURPOSE: The pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of olaparib, a first-in-class treatment for advanced treatment-refractory ovarian cancer, are reviewed. SUMMARY: Olaparib (Lynparza, AstraZeneca) is an oral inhibitor of poly(ADP-ribose) polymerase (PARP) proteins that play a key role in DNA repair and genomic stability. Olaparib is indicated for use in treating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Mutation

Share to Ovarian Neoplasms

Share to Phthalazines

Share to Piperazines

Share to Treatment Outcome

Source

Identifiers

PMID: 27385701
DOI: 10.2146/ajhp150550

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Olaparib for the treatment of BRCA-mutated advanced ovarian cancer.PMID 27385701Read ↗

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.Semantic proximity Read ↗

The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.Semantic proximity Read ↗

Olaparib and advanced ovarian cancer: Summary of the past and looking into the futureSemantic proximity Read ↗

Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancerSemantic proximity Read ↗

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.Semantic proximity Read ↗

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.Semantic proximity Read ↗

Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation.Semantic proximity Read ↗

Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian CancerSemantic proximity Read ↗

Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer.Semantic proximity Read ↗

PARP Inhibitors in Ovarian Cancer: A ReviewSemantic proximity Read ↗

PARP inhibitors in ovarian cancer.Semantic proximity Read ↗

Olaparib for the treatment of breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.